ResMed (RMD)
(Delayed Data from NYSE)
$244.28 USD
+1.81 (0.75%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $244.21 -0.07 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$244.28 USD
+1.81 (0.75%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $244.21 -0.07 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth A Momentum A VGM
Zacks News
ResMed (RMD) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 7.01% and 7.95%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Reasons Why You Should Retain ResMed (RMD) Stock For Now
by Zacks Equity Research
Investors are optimistic about ResMed's (RMD) Increased demand for its digital health solution.
EYE vs. RMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EYE vs. RMD: Which Stock Is the Better Value Option?
Reasons Why You Should Retain ResMed (RMD) Stock For Now
by Zacks Equity Research
Investors are optimistic about ResMed (RMD) owing to the increased demand for its sleep and respiratory care devices.
Top Research Reports for Chevron, Novo Nordisk & Amgen
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), Novo Nordisk A/S (NVO) and Amgen Inc. (AMGN).
ResMed's (RMD) Mask Sales Drive Growth, Margin Issue Lingers
by Zacks Equity Research
ResMed (RMD) continues to see robust demand for its market-leading mask portfolio despite being faced with challenges related to lower new patient setups from a competitor recall.
ESLOY vs. RMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
ESLOY vs. RMD: Which Stock Is the Better Value Option?
ResMed's (RMD) Q2 Earnings Beat Estimates, Margins Falls
by Zacks Equity Research
ResMed's (RMD) mask sales growth was strong across the globe, reflecting a post-COVID pandemic awareness about the importance and need for respiratory hygiene and respiratory health.
ResMed (RMD) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 3.75% and 3.64%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Home Depot, Merck, Bank of America, Elevance Health and ResMed
by Zacks Equity Research
Home Depot, Merck, Bank of America, Elevance Health and ResMed are included in this Analyst Blog.
Top Analyst Reports for Home Depot, Merck & Bank of America
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), Merck & Co., Inc. (MRK) and Bank of America Corporation (BAC).
ResMed (RMD) Q1 Earnings In Line, Operating Margin Falls
by Zacks Equity Research
ResMed (RMD) continues to increase its access to semiconductor communications chips.
ResMed (RMD) Q1 Earnings Match Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 0% and 0.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Landec (LNDC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Landec (LNDC) delivered earnings and revenue surprises of -166.67% and 1.89%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?
ResMed (RMD) Gains on Product Uptake Even as Expenses Rise
by Zacks Equity Research
The continued uptake of ResMed's (RMD) core non-invasive ventilation and life support ventilation solutions for COPD and neuromuscular disease is encouraging.
Reasons Why You Should Retain ResMed (RMD) Stock For Now
by Zacks Equity Research
Investors are optimistic about ResMed's (RMD) better-than-expected results and robust device sales.
ResMed (RMD) Q4 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
ResMed (RMD) posts better-than-expected Q4 results with continued strength in sleep and respiratory care devices sales performance.
ResMed (RMD) Q4 Earnings Beat Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 0.68% and 0.29%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ResMed Q4 Preview: Rebound Quarter Inbound?
by Derek Lewis
RMD has primarily exceeded the Zacks Consensus EPS Estimate. However, the company registered an 8% bottom-line miss in its latest quarter.
Nephros Inc. (NEPH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nephros Inc. (NEPH) delivered earnings and revenue surprises of 14.29% and 6.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
NuVasive (NUVA) Lags Q2 Earnings Estimates
by Zacks Equity Research
NuVasive (NUVA) delivered earnings and revenue surprises of -14.55% and 1.51%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
AngioDynamics (ANGO) Q4 Earnings in Line, Revenues Beat Mark
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in Med Tech and Med Device businesses, as well as in its GBUs, in fourth-quarter fiscal 2022.
Reasons Why You Should Invest in ResMed (RMD) Stock Now
by Zacks Equity Research
Investors are optimistic about ResMed's (RMD) robust mask and device sales and continued product innovations.